Investigational drug · Phase 2
Dual-target CAR-NK cells
Also called: EB-DT-CAR-NK, Essen Biotech Dual-Target CAR-NK
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2-positive Breast Cancer, Non-Small Cell Lung Cancer, Breast Cancer (Locally Advanced or Metastatic).
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
31
Any phase or sponsor naming "Dual-target CAR-NK cells"
First trial start
2026
Feb 2, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Dual-target CAR-NK cells", any sponsor or status.
Conditions studied
As listed on its trial records.
- HER2-positive Breast Cancer
- Non-Small Cell Lung Cancer
- Breast Cancer (Locally Advanced or Metastatic)
- Triple-Negative Breast Cancer (TNBC)
- Advanced Gastric Adenocarcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
- Advanced/Metastatic
- Breast Cancer (Advanced/Metastatic)
- Triple-negative Breast Cancer
- Advanced/Metastatic NSCLC
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Dual-target CAR-NK cells" as an intervention, largest first.
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07307053 · 600 participants (planned) · Start Jan 1, 2026 · Primary completion Jan 31, 2029
Drug: BL-B01D1; VSV injection and 18 more · For: Rare Malignant Neoplasm; Advanced Solid Tumors; Metastatic Solid Tumors
Sung-Soo ParkAcademic, hospital or other
NCT07051850 · 174 participants (planned) · Start Jul 14, 2025 · Primary completion Dec 31, 2025
Drug: Bispecific antibody; Antibody-Drug Conjugate and 4 more · For: Multiple Myeloma, Relapsed; Multiple Myeloma (MM)
Sites: Seocho, South Korea
Essen BiotechAcademic, hospital or other
NCT07410494 · 85 participants (planned) · Start Feb 1, 2026 · Primary completion Dec 28, 2027
Drug: EB-SELECT Single-Target CAR-NK Cells; Dual-Target Antigen-Selected CAR-NK · For: Cancer; Breast Cancer; Non-Small Cell Lung Cancer (NSCLC) and 10 more
Sites: Beijing, China
- Immunotherapy in LymphomaRecruiting
Sung-Soo ParkAcademic, hospital or other
NCT06796517 · 72 participants (planned) · Start Jun 26, 2024 · Primary completion Dec 2025
Drug: CAR-T Therapy; Bispecific antibody and 4 more · For: Relapsed/refractory High Grade B Cell Lymphoma; High Grade B-cell Lymphoma; Diffuse Large B Cell Lymphoma Relapsed and 2 more
Sites: Seoul, South Korea · 2 sites in all
Beijing BiotechIndustry
NCT07510802 · 60 participants (planned) · Start Feb 2, 2026 · Primary completion Mar 14, 2027
Drug: Dual-target CAR-NK cells; Lymphodepleting · For: Breast Cancer (Advanced/Metastatic); HER2-positive Breast Cancer; Triple-negative Breast Cancer
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07480213 · 60 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 14, 2027
Drug: EB-DART-NK01 (DLL3/CD56 CAR-NK cells); Lymphodepleting chemotherapy · For: Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; SCLC, Extensive Stage
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07641023 · 60 participants (planned) · Start Mar 2, 2026 · Primary completion Mar 14, 2027
Drug: Dual-target CAR-NK cells; Lymphodepleting chemotherapy · For: Non-Small Cell Lung Cancer; Advanced/Metastatic
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07486089 · 60 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 14, 2027
Drug: Dual-target CAR-NK cells (EB-DT-CAR-NK); Lymphodepleting chemotherapy · For: Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer; Triple-Negative Breast Cancer (TNBC)
Sites: Shenzhen, China
- PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid TumorsRecruiting
Beijing BiotechIndustry
NCT07510828 · 60 participants (planned) · Start Mar 2, 2026 · Primary completion Mar 14, 2027
Drug: EB-PT-CAR-NK-S; EB-PT-CAR-NK-D and 2 more · For: Advanced or Metastatic Solid Tumors
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07744256 · 60 participants (planned) · Start Mar 2, 2026 · Primary completion Feb 14, 2027
Drug: EB-DART-NK01; Lymphodepleting chemotherapy · For: Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; Extensive-stage SCLC
Sites: Shenzhen, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for HER2-positive Breast Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- DP303cPhase 34 trials
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · HER2-positive Breast Cancer, Advanced Solid Tumors, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
- IBI354Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Locally Advanced Unresectable or Metastatic Solid Tumors, Ovarian, Primary Peritoneal
- A166Phase 32 trials
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Her 2 Positive Breast Cancer, HER2-positive Breast Cancer
- ZN-A-1041ZN-A-1041 Enteric, RO7771950Phase 32 trials
Roche (Genentech) · HER2-positive Breast Cancer, Advanced Solid Tumors
- GQ1005Phase 31 trial
GeneQuantum Healthcare (Suzhou) Co., Ltd. · HER2-positive Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.